AGE Stock Analysis
AG
Uncovered
AgeX Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm's product pipeline includes two cell-based therapies, which is derived from telomerase-positive pluripotent stem cells (PSCs) and two product candidates, which is derived from its induced Tissue Regeneration (iTRTM) technology. The firm's AGEX-BAT1 is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. Its AGEX-VASC1 is designed to restore vascular support in aged ischemic tissues, such as the aging heart. The firm's iTRTM technology product candidates include AGEX-iTR1547, which is a drug-based formulation, and AGEX-iTR1550 (Renelon), which is a gene delivery technology.